

Pharma in brief - Canada

Health Canada releases revised fact sheet on biosimilars

Fact sheet: Fact Sheet: Biosimilars [**Fact Sheet**]
Date: Revised December 7, 2016
Related enactments: *Food and Drugs Act*, RSC 1985, c F-27
Food and Drug Regulations, CRC, c 870 [**Food and Drug Regulations**]

Summary

Health Canada has revised its fact sheet on biosimilar biologic drugs (**biosimilars**), which were formerly known as subsequent-entry biologics. This update follows Health Canada's recent revisions to the *Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs* (the **Guidance Document**).

Highlights

In line with recent changes to the *Guidance Document*, the *Fact Sheet* has been substantially rewritten and contains an overview and description of the regulatory framework for biosimilars. The *Fact Sheet* also includes a new section on drug and patient access, which includes the following:

- Health Canada's authorization of a biosimilar is independent of provincial, territorial, or private drug plan decisions regarding its formulary listing and reimbursement.
- Health Canada's authorization of a biosimilar is not a declaration of equivalence between the biosimilar and its reference biologic drug, and is independent of any decision as to interchangeability between these drugs. Interchangeability decisions are a matter of provincial and territorial jurisdiction.
- Health Canada recommends that decisions regarding switching to a biosimilar from its reference biologic drug should be made by treating physicians in consultation with the patient.

For more information on Health Canada's revised approach to the regulation of biosimilars, see our report on the full *Guidance Document* [here](#).

Links:

- Fact Sheet:** [Fact Sheet: Biosimilars](#)
- Guidance Document:** [Information and Submission Requirements for Biosimilar Biologic Drugs \(November 14, 2016\)](#)
- Previous documents:** [Guidance For Sponsors: Information and Submission Requirements for Subsequent Entry Biologics \(SEBs\) \(March 5, 2010\)](#)
[Draft - Revised Guidance Document: Information and Submission Requirements for Subsequent Entry Biologics \(SEBs\) \(December 7, 2015\)](#)
- Related enactments:** [Food and Drugs Act, RSC 1985, c F-27](#)
[Food and Drug Regulations, CRC, c 870](#)

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For a complete list of our IP team, [click here](#). For a complete list of our Life sciences and healthcare team, [click here](#).

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to "Norton Rose Fulbright", "the law firm", and "legal practice" are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together "Norton Rose Fulbright entity/entities"). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a "partner") accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.